NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $15.84 0.00 (0.00%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$15.76 -0.08 (-0.52%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AUPH alerts:Sign Up Key Stats Today's Range$15.82▼$16.7050-Day Range$13.98▼$16.4252-Week Range$7.28▼$16.88Volume1.28 million shsAverage Volume1.28 million shsMarket Capitalization$2.04 billionP/E Ratio7.30Dividend YieldN/APrice Target$17.25Consensus RatingHold Company Overview Aurinia Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline. The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S. Food and Drug Administration for the treatment of adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Beyond lupus nephritis, Aurinia is investigating voclosporin in additional indications such as focal segmental glomerulosclerosis (FSGS) and dry eye disease, with several ongoing clinical trials to evaluate safety and efficacy. Founded in the early 1990s, Aurinia is headquartered in Victoria, British Columbia, and maintains a presence in North America to support its clinical and commercial activities. The company’s leadership team comprises experienced professionals in drug development, regulatory affairs and commercial operations, guiding Aurinia through pivotal clinical milestones and into its initial product launch. As Aurinia continues to expand its pipeline and explore partnerships, it remains committed to addressing unmet needs in autoimmune disease management.AI Generated. May Contain Errors. Read More Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreAUPH MarketRank™: Aurinia Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 457th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, 4 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Aurinia Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-2.44% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to decrease by -2.44% in the coming year, from $0.82 to $0.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is 7.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is 7.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.87.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Aurinia Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.99% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 6.79.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 1.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.13 News SentimentAurinia Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest14 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.MarketBeat Follows8 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $12,455,129.00 in company stock, which represents 0.6114% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,455,129.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AUPH Stock News HeadlinesAurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 MillionJune 7 at 9:04 AM | fool.comAurinia: Cash-Generating Today, Pipeline-Driven TomorrowJune 4, 2026 | seekingalpha.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 8 at 1:00 AM | Porter & Company (Ad)LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or DeathJune 4, 2026 | financialpost.comFLUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or DeathJune 4, 2026 | businesswire.comKevin Tang Acquires 264,981 Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) StockJune 4, 2026 | americanbankingnews.comKevin Tang Buys 206,005 Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) StockJune 4, 2026 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) CEO Acquires $3,147,756.40 in StockJune 3, 2026 | insidertrades.comSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $15.95 at the beginning of the year. Since then, AUPH shares have decreased by 0.7% and is now trading at $15.84. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its earnings results on Thursday, May, 7th. The biotechnology company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.18 by $0.07. The biotechnology company had revenue of $77.71 million for the quarter, compared to analysts' expectations of $76.98 million. Aurinia Pharmaceuticals had a net margin of 99.97% and a trailing twelve-month return on equity of 26.62%. Who are Aurinia Pharmaceuticals' major shareholders? Top institutional investors of Aurinia Pharmaceuticals include Arrowstreet Capital Limited Partnership (2.55%), Renaissance Technologies LLC (1.29%), Janus Henderson Group PLC (0.59%) and Rice Hall James & Associates LLC (0.38%). Insiders that own company stock include Kevin Tang, Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Greg Keenan and Jeffrey Allen Bailey. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/07/2026Today6/08/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 AUPH's financial health is in the Green zone, according to TradeSmith. AUPH has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUPH CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year Founded2013Price Target and Rating Average Price Target for Aurinia Pharmaceuticals$17.25 High Price Target$21.00 Low Price Target$15.00 Potential Upside/Downside+8.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$2.17 Trailing P/E Ratio7.30 Forward P/E Ratio19.32 P/E GrowthN/ANet Income$287.20 million Net Margins99.97% Pretax Margin44.83% Return on Equity26.62% Return on Assets19.65% Debt Debt-to-Equity Ratio0.08 Current Ratio5.55 Quick Ratio5.01 Sales & Book Value Annual Sales$298.30 million Price / Sales6.83 Cash Flow$1.01 per share Price / Cash Flow15.63 Book Value$4.41 per share Price / Book3.59Miscellaneous Outstanding Shares128,602,000Free Float112,913,000Market Cap$2.04 billion OptionableOptionable Beta1.41 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:AUPH) was last updated on 6/8/2026 by MarketBeat.com Staff. From Our PartnersThe "hidden" half of the SpaceX IPOMost investors are focused on the SpaceX IPO - but the bigger opportunity may lie elsewhere. On Feb. 2, Elon M...Weiss Ratings | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)The media's calling it "the biggest IPO in Wall Street history." But I'm not buying it. Institutions got into ...Decentralized Masters | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredSpaceX billions need somewhere to go — this is itThe SpaceX IPO is projected to raise $75 billion in a single day... When that happens, the insiders who cashed...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
